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Hydrated clearance of gadolinium-DTPA as a measurement of glomer.
ular filtration rate. Technetium (ssmTc)diethylene triamine pentaacetic
acid (DTPA) hydrated clearance studies are accurate for determining
GFR but require special facilities for handling and measuring samples.
We investigated the potential of a non-radioactive paramagnetic analog,
Gadolinium (Gd)-diethylene triamine pentaacetic acid (DTPA), an
approved NMR contrast agent, as a glomerular filtration marker.
Instead of relying on the radioactivity of technetium, this test is based
on the fact that gadolinium induces alterations in the NMR Ti relax-
ation times in blood and urine samples. Ninety patients underwent
simultaneous determinations of GFR using I mCi of Tc-DTPA and 0.05
mmol/kg Gd-DTPA (Berlex Labs) IV. The patients were hydrated with
oral and intravenous fluid. Following a one hour equilibrium period,
three or four consecutive urine collections were obtained; plasma
samples were acquired at the beginning and end of each approximately
20-minute interval. mTcDTPA radioactivity was determined with a
scintillation counter. Ti relaxation times were measured on a 10 MHz
NMR spectrometer. These were converted to Gd-DTPA concentration
by comparison with standard solutions. The Gd-DTPA derived GFR
closely approximated the mTcDTPA derived GFR which ranged from
15 to 147 mi/mm. The equation and correlation coefficient of the
regression line is y = 1.04 x —2.2, r = 0.94. Thus, Gd-DTPA is a safe,
non-radioactive indicator of GFR that may provide an alternative renal
clearance method for clinical studies of progressive renal disease and
nephrotoxicity.
Accurate determinations of glomerular filtration rate (GFR)
are required for assessing renal disease progression or nephro-
toxicity associated with therapeutic agents. In clinical practice,
the serum creatinine and/or the creatinine clearance have been
employed as estimates of GFR. Although this approach is
convenient, the creatinine clearance is not a true measure of
GFR [1]. The creatinine clearance may overestimate GFR by
50% for patients with moderate renal insufficiency (GFR 40 to
80 ml/min/l.73 m2) and by 100% for patients with severe renal
insufficiency (GFR <40 ml/min/l.73 m2) [21.
To overcome this problem, investigators have employed
filtration markers such as inulin, sodium iothalamate, and
diethylene triamine pentaacetic acid (DTPA) to determine
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GFR. Although inulin clearance techniques have been widely
employed, the chemical assay of inulin concentration in urine
and plasma is associated with technical difficulties [1—41. So-
dium meglumine iothalamate and other iodinated contrast me-
dia (such as, iohexol) can be detected with X-ray fluorescence
or HPLC; however, this requires a potentially nephrotoxic
iodinated contrast medium [5, 6].
Over the past 20 years radiolabelled filtration markers such as
99mTechnetjum..DTPA [2, 7, 8], '25iodine-iothalamate [9], and
51chromium-EDTA [101 have become widely available for uri-
nary clearance studies. mTechnetium (Tc)-DTPA requires a
relatively small dose of radioactivity and has a short (6 hr)
half-life. Instead of directly measuring the chemical concentra-
tion of the filtration marker, the radioactivity of the samples is
substituted for concentration in the clearance formula [7, 8, 10].
Disadvantages of radioactive filtration markers are that they
require licensed nuclear medicine facilities and personnel. The
patient is exposed to a small dose of radioactivity which is
concentrated in the pelvis. Samples must be counted relatively
quickly since the radioactivity decays with time.
We have investigated the use of a non-radioactive filtration
marker, Gadopentetate-dimeglumine (Gd-DTPA, Magnevist,
Berlex Laboratories, Cedar Knolls, New Jersey, USA), which
is an FDA approved radiographic contrast agent employed in
Nuclear Magnetic Resonance (NMR) Imaging studies. The
enhancement properties of Gd-DTPA derive from the effect this
molecule has on the relaxation properties of surrounding human
tissues and body fluids. Relaxation parameters are of two types,
spin-lattice relaxation time, Tl, and spin-spin relaxation time,
T2, which is much less affected by Gd-DTPA at typical imaging
concentrations. Gadolinium is paramagnetic which is the prop-
erty whereby an element or ion, when placed in a magnetic
field, develops its own magnetic properties (that is, induces
local magnetic fields around the ion). Thus, Gd-DTPA shortens
both the Ti and to a lesser degree the T2 relaxation times of
surrounding tissues or fluids by altering the local magnetic field.
These changes in relaxation times can be utilized to determine
the concentration of Gd-DTPA in plasma and urine samples
since there is a linear correlation between Gd-DTPA concen-
tration and the inverse of Ti, also known as the Ti relaxation
rate. The purpose of this report is to describe a novel method to
1595
1596 Choyke et a!: Hydrated clearance of gadolinium-DTPA
measure GFR using Gd-DTPA and to compare it to 99mTc
DTPA as a filtration marker.
Methods
Patient selection and preparation
The patients were studied to monitor the nephrotoxic effects
of cyciosporine therapy for autoimmune uveitis (N = 62) and
multiple sclerosis (N = 13) as well as to study individuals with
membranous nephropathy (N = 15).
Prior to a hydrated clearance study, each patient drank a
loading dose of water (20 mI/kg). A dilute diuresis was main-
tained with oral fluids and intravenous Dextrose 5% water at
300 to 450 ml/hr. Diet on the morning of the study was restricted
to low salt, low protein food and non-caffeinated beverages.
Oral perchiorate was administered 30 minutes prior to the study
to block thyroid uptake of 99mTcDTPA. Plasma and urine
samples (P1 and Ut) were obtained just prior to injection of the
filtration markers. The patient received 1 mCi mTcDTPA and
0.05 mmol/kg of Gd-DTPA (10 patients received 0.1 mmol/kg
Gd-DTPA), and a one hour period or equilibrium was allowed
to elapse before urine collections were initiated. The 99mTc
DTPA was routinely assessed for radiochemical purity and was
always greater than 99% bound with less than 1% free ion.
Sample collections
Once a dilute diuresis had been achieved, three consecutive
timed (approximately 20 mm) urine collections, bracketed by 5
cc blood samples in heparinized syringes, were obtained. The
volume and time of each urine collection were accurately
recorded.
Radioactivity measurements
Separate samples were obtained for assay of radioactivity
and for Ti relaxation time determinations. We first confirmed
that mTcDTPA had no effect on Ti relaxation times of plasma
and urine, The blood specimens were centrifuged (7500 RPM
for 10 mm), and 0.6 cc aliquots of plasma and urine were
counted in triplicate in an automated scintillation counter
(Packard Gamma Cobra, Sterling, Virginia, USA). Background
counts were subtracted to obtain corrected radioactivity
counts; this corrected radioactivity (CPM) value was substi-
tuted in the standard urinary clearance formula to calculate
GFR [101.
NMR analysis
TI relaxation times were determined on the plasma and urine
samples employing a 10 MHz NMR spectrometer (Praxis, San
Antonio, Texas, USA) at a constantly maintained 21°C. The
determination of Ti is an automated procedure utilizing pulse
programming and curve fitting software. Each T 1 determination
was repeated once and the results averaged.
To obtain the Ti, the sample was placed in the NMR
spectrometer. Using a series of 90° radio frequency (RF) pulses
separated by a given time, tau (90-tau-90 sequence), the ampli-
tude of the returning resonant radio frequency signal was
measured. The tau value was progressively changed in even
steps so that a curve composed of 25 separate points was
measured and fitted to an exponential equation. Tl is defined as
Gd-DTPA concentration, m
Fig. 1. Graph depicting method of determining Gd-DTPA concentra-
tion from TI relaxation times. Three standards (0, 35 and 170 M) are
used to define the line [Gd-DTPA] vs. 1/Ti. In the example, the Ti of
the specimen was 166 ms (I/TI = 0.0062 msec). Thus, the Gd-DTPA
concentration in that sample is 0.093 m or 93 ELM.
the time taken for the signal intensity to exponentially decay to
67% of the initial peak value and is given in units of seconds.
In order to calibrate the Ti values with actual Gd-DTPA
concentrations, pre-injection samples (P1 and Ui) were divided
into three equal volumes and two were "doped" with known
amounts of Gd-DTPA thus obtaining two standards for plasma
(PSi and PS2) and two standards for urine (US1 and US2). The
Tl relaxation times for these samples were determined.
Separate linear least squares lines of the Ti relaxation rate
(1/Ti) versus Gd-DTPA concentration were derived for plasma
and urine employing three points (P1, PSi and PS2) for plasma
and three points (UI, USI, US2) for urine. These lines are used
to calculate the Gd-DTPA concentration in the remaining
samples. This is illustrated in Figure 1 where a sample 1/Ti
versus Gd-DTPA line has been derived. In the example, a
sample taken from one of the intervals measures Ti = 166 ms
and thus, 1/Ti (0.006 sec'). The actual Gd-DTPA concentra-
tion (0.093 mM) can then be determined as shown.
Once the Gd-DTPA concentrations have been determined
employing the above method, the interval GFR was calculated
with the standard clearance equation:
GFR = [U1] * V1/[mean P, — , PJ
Where V1 equals the interval urine flow rate (mi/mm), U1 is the
Gd-DTPA concentration in urine obtained from interval and
mean P_1, P represents the average concentration of Gd-
DTPA in the plasma samples bracketing the urine collection.
The interval GFR values were then averaged.
Data analysis
The correlation coefficient, slope and intercept, of the linear
regression of 99mTcDTPA versus Gd-DTPA derived GFR
values were obtained, and 95% confidence intervals for slope
and intercept were determined [11], The standard error of the
estimate (SEE) was also calculated for the regression line. The
SEE is a measure of the extent to which the Gd-DTPA GFR
values estimated from the line deviate from those actually
observed.
We determined the intra-assay coefficients of variation (CV =
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methods of measuring GFR [121. The intra-assay CV depicts the
variation among replicate determinations of GFR within a urine
collection interval. The between interval CV indicates the
variation among GFR values between urine collection intervals.
We also calculated the inter-assay CV which depicts the vari-
ation between determinations of GFR using the two different
filtration markers studied.
To assess whether incomplete voiding might disproportion-
ately affect Gd-DTPA GFR values due to dependent layering of
Gd-DTPA, the difference between 99mTc..DTpA and Gd-DTPA
GFR values for each interval was calculated (delta clearance).
The between interval CV of the delta clearance was then
correlated with the between interval CV of mTcDTPA GFR
using linear regression. If the between interval CV of the delta
clearance were significantly correlated with the between inter-
val CV ofmTcDTpA, then one could conclude that variations
in bladder emptying probably affected Gd-DTPA and mTc
DTPA GFR determinations differently.
Results
Results have been obtained in 90 patients. GFR values varied
between 15 and 147 mI/mm. A scatter plot of the comparison of
99mTcDTPA versus Gd-DTPA hydrated clearance GFR deter-
minations for each patient is depicted in Figure 2. This demon-
strates a regression line with the following equation:
y= l.04x—2.2,r=0.94
The 95% confidence interval for the slope is 1.00 to 1.08, and
the 95% confidence interval for the intercept is +6.2 to —10.2.
The standard error of the estimate (SEE) for Gd-DTPA GFRs
was 6.5 cc/mm.
The intra-assay CVs for replicate Gd-DTPA and Tc-DTPA
GFR determinations were 3.2% and 2.3%, respectively. The
between interval CVs for Gd-DTPA and Tc-DTPA GFR values

















were 8.9% and 6.8%, respectively. The interassay CV for
Gd-DTPA and Tc-DTPA GFR determinations was 3.6%.
The correlation coefficient of the linear regression of the
between interval CV of delta clearance versus the between
interval CV of Tc-DTPA GFR was r = 0.38, which indicates a
poor correlation. Thus, there is no evidence in this study that
variations in bladder emptying affect Gd-DTPA and Tc-DTPA
GFR determinations differently.
Discussion
The accurate measurement of GFR is essential to character-
ize renal function particularly if patients are being monitored for
the development of nephrotoxicity or for progression of an
underlying renal disease [131. The Gd-DTPA clearance based
on the measurement of i/Tl relaxation rates provided accurate
GFR determinations that closely correlate with 99mTc..DTpA
derived measurements. The only specialized equipment re-
quired to perform this test is a desktop NMR spectrometer that
can measure Tl. A spectrometer, including computer and
software sufficient for this application costs between $20,000 to
$50,000 depending on what other features are desired. While Ti
measurements can be unreliable in solid tissues because of
sample heterogeneity, the Ti values in homogeneous fluids
such as serum and urine are accurate and reproducible. More-
over, there is a linear relationship between the Ti relaxation
rate (i/Ti) and Gd-DTPA concentration over the range of serum
and urine Gd-DTPA concentrations in this study [14—17].
Gd-DTPA has been safely administered to patients with renal
impairment (creatinine clearance 20 to 80 mI/mm) with no
change in renal function [14, 16]. Gadolinium-DTPA, like
99mTc..DTPA, is cleared in a biexponential manner. It equili-
brates with the extravascular space within one hour (t"2 = 12
mm) and is excreted via the kidneys (t"2 1.6 hr). No
detectable Gadolinium is present in patients by 24 hours except
those with severely dysfunctional kidneys. For patients with a
GFR less than 20 mI/mm, the elimination of Gd-DTPA is
prolonged (t"2> 30 hr), and while no toxicity has been reported
in these patients, the experience remains limited [16, 18]. A
comparison of Gd-DTPA and mTcDTPA is shown in Table 1.
According to the manufacturer there is no detectable decom-
position of Gd-DTPA compound in vivo since it has a very large
binding coefficient (K = 1023).
Although urinary bladder retention of filtration markers is a
potential source of error in all clearance studies, there is no
evidence from these results that Gd-DTPA GFR determinations
would be affected differently than Tc-DTPA GFR. To avoid this
problem in patients with known voiding dysfunction, drainage
catheters are usually required.
The accuracy of TI measurements can also be influenced by
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Fig. 2. A comparison of Tc-DTPA derived GFR values to Gd-DTPA
derived GFR values.
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to minimize these affects by mixing each sample prior to
measurement. The NMR spectrometer was kept in one location
and measurements were performed at a constant temperature.
The 90-tau-90 method of Ti determination, while faster than
180-tau-90 methods, is slightly less accurate when Ti values are
short [19]. Such a situation can arise in urine samples with
highly concentrated Gd-DTPA where the relationship between
relaxation rate and Gd-DTPA concentration may become non-
linear. In the dose range of this study (0.05 mmol/kg to 0.1
mmollkg), highly concentrated Gd-DTPA in the urine was
avoided. The smaller dose (0.05 mmol/kg Gd-DTPA) became
our standard because it reduced the cost of the examination.
There was no need to dilute urine samples to lower the
concentration into the linear range. The effect of hemolysis on
plasma T1 values are minimal if the blood samples are centri-
fuged promptly and if the eluted plasma samples are stored at
5°C (as done in this study) [12].
Gd-DTPA GFR measurement is readily adapted to the clini-
cal environment. The entire measurement procedure can be
automated and results are available quickly. The absence of
ionizing radiation permits the study to be performed at the
bedside, ward or at any other convenient location. Unlike
radioactive filtration markers, Gd-DTPA does not decay and
thus measurements can be repeated, if necessary, at a later
date. Gd-DTPA is widely available throughout the world (Ber-
lex Laboratories in North America, Schering in Europe and
world wide), is well tolerated and could be combined with an
MRI imaging study if desired.
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